The merger between Venaxis and Strand Life Sciences will initially focus on developing StrandAdvantage tests with further expansion expected.
Venaxis, a Castle Rock, CO-based developer of an in vitro diagnostic test for acute appendicitis, has announced plans to acquire Strand Life Sciences, an India-based cancer genomics firm that has U.S. headquarters in Aurora, CO.
“We are pleased to announce this transaction and are excited by the significant opportunity we believe it presents for shareholders of Venaxis and Strand LS,” Steve Lundy, CEO of Venaxis said in the release. “Our initial focus will be to improve patient outcomes through the use of the StrandAdvantage pan-cancer gene panel, which was commercially launched in the United States in 2015. The combined company is expected to be focused on the continued commercialization of StrandAdvantage, as well as the development of additional oncology-related diagnostics.” For the full article click here
from health IT caucus http://ift.tt/1KCP8CE
via IFTTT
No comments:
Post a Comment